Discover 1,541 paid clinical trials in Jersey City, New Jersey. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,541
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
for
Major Depressive Disorder
Location: The Bronx NY, Inwood NY, Princeton NJ, Toms River NJ,
Sponsor: Neumora Therapeutics, Inc.
Sex: All
Age: 18 - 65
Code: NCT06058013
Phase3, Recruiting
Active & Responsive
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
for
Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms,
Location: Jersey City NJ, Newark NJ, Belleville NJ, Elizabeth NJ,
Sponsor: Rutgers, The State University of New Jersey
Sex: All
Age: 18+
Code: NCT07158164
Recruiting
Active & Responsive
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
for
SARS-CoV-2
Location: Jersey City NJ, Stamford CT, Kenner LA, Bridgeport CT,
Sponsor: ModernaTX, Inc.
Sex: All
Age: 50 - 64
Code: NCT07266558
Recruiting
Active & Responsive
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
for
Psoriasis, Overweight or Obesity
Location: Hoboken NJ, New York NY, East Windsor NJ,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06857942
Recruiting
Active & Responsive
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
for
Ductal Carcinoma in Situ
Location: New York NY, Englewood NJ, Wynnewood PA, Bryn Mawr PA,
Sponsor: QuantumLeap Healthcare Collaborative
Sex: Female
Age: 18+
Code: NCT06075953
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
for
Metastatic Head and Neck Squamous Cell Carcinoma,
Location: New York NY, Newark NJ, Hackensack NJ, Newark DE,
Sponsor: Bicara Therapeutics
Sex: All
Age: 18+
Code: NCT06788990
Phase2, Phase3, Recruiting
Active & Responsive
Caris Biorepository Research Protocol
for
Cancer, Early Detection of Cancer, Minimal Residual Disease